Frontiers in Immunology · 2022 · 34 citations · 14 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccinologyVirologyAntiviral ImmunityImmune Response To VaccinationMrna Vaccine TechnologyVaccinationVaccine EffectivenessVaccine EfficacyCoronavirus VaccinesImmunological AssaysImmunological ResponseMedian AgeMessenger Rna (Mrna) VaccinesObservational Study AnalysisSars-cov-2 InfectionVirological Diagnosis
This study aims to assess the immunological response and impact on virological control of the mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with HIV (PLWH). In this single-center observational study, all PLWH were offered vaccination with mRNA1273 or BNT162b2. Both anti-N and anti-S1-receptor binding domain (RBD) antibodies were measured together with HIV-1 RNA levels after the first dose (M0) and then at 1 (M1), 2 (M2) and 6 (M6) months later. A total of 131 individuals (median age: 54 years [IQR: 47.0-60.5]; male: 70.2%; median baseline CD4 T-cell: 602/µl [IQR 445.0-825.5]; median nadir CD4 T-cells 223/µl [IQR 111.0-330.0]) were included. All participants were positive for anti-RBD antibodies at 30 days, 60 days and 6 months after the first dose, with no statistical difference between those with HIV-1 RNA below or >20 copies/ml. HIV-1 RNA data were collected for 128 patients at baseline and 30 days after the first dose; for 124 individuals, 30 days after the second dose; and for 83 patients, 6 months after the first dose. Nineteen (14.8%) of 128 had detectable HIV-1 RNA (>20 copies/ml) at M0, 13/128 (10.2%) at M1 (among which 5 were newly detectable), 15/124 (12.1%) at M2 (among which 5 were newly detectable), and 8/83 (9.6%) at M6. No serious adverse effects were reported. All participants elicited antibodies after two doses of mRNA vaccines, with only a minor impact on HIV-1 RNA levels over a 6-month period.
14
Andrew Boulle, Mary‐Ann Davies, Hannah Hussey et al. · Clinical Infectious Diseases · 2020 · 598 citations · Full text
Veterinary Medicine, Health Sciences, Infectious Diseases +17
Krishnan Bhaskaran, Christopher T. Rentsch, Brian MacKenna et al. · The Lancet HIV · 2020 · 466 citations · Full text
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Alfredo Addeo, Pankil Shah, Natacha Bordry et al. · Cancer Cell · 2021 · 243 citations · Full text
Medicine, Immunology, Oncology +12